Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Inhibikase Therapeutics (IKT) Non Operating Investment Income (2022 - 2026)

Inhibikase Therapeutics (IKT) has 5 years of Non Operating Investment Income data on record, last reported at -$48095.0 in Q1 2026.

  • On a quarterly basis, Non Operating Investment Income fell 232.56% to -$48095.0 in Q1 2026 year-over-year; TTM through Mar 2026 was -$25326.0, a 3140.34% decrease, with the full-year FY2025 number at $59050.0, up 254.89% from a year prior.
  • Non Operating Investment Income reached -$48095.0 in Q1 2026 per IKT's latest filing, down from $25991.0 in the prior quarter.
  • Over the last five years, Non Operating Investment Income for IKT hit a ceiling of $36281.0 in Q1 2025 and a floor of -$167536.0 in Q2 2023.
  • A 5-year average of -$13858.9 and a median of -$234.5 in 2024 define the central range for Non Operating Investment Income.
  • On a YoY basis, Non Operating Investment Income climbed as much as 1455.29% in 2025 and fell as far as 354.77% in 2025.
  • Tracing IKT's Non Operating Investment Income over 5 years: stood at $26828.0 in 2022, then tumbled by 94.14% to $1571.0 in 2023, then plummeted by 2582.62% to -$39002.0 in 2024, then surged by 166.64% to $25991.0 in 2025, then tumbled by 285.04% to -$48095.0 in 2026.
  • Business Quant data shows Non Operating Investment Income for IKT at -$48095.0 in Q1 2026, $25991.0 in Q4 2025, and -$1245.0 in Q3 2025.